Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Seikagaku to Conduct Add'l Clinical Trial for SI-6603 in Japan
August 29, 2011
- Drug Wholesalers' Operating Profit Rate at Record Low 0.13% in FY2010: JPWA
August 29, 2011
- Chugai Files Application for Add'l Indication for Kytril Based on Data in Public Domain
August 29, 2011
- Kyowa Kirin Initiates PIII Trial of ARQ197 for NSCLC in Asian Countries
August 29, 2011
- Teijin Pharma, Astellas Sign New Marketing Agreement on Febuxostat
August 29, 2011
- Astellas, Kyowa Kirin Apply for Higher Doses of Amoxicillin Based on Data in Public Domain
August 29, 2011
- AnGes MG Granted Pharmaceutical Use Patent for Ets-1 in US
August 29, 2011
- Chugai Licenses Melanoma Treatment Vemurafenib from Roche; PI Trial to Begin in 2012
August 29, 2011
- Pfizer Japan Withdraws NDA for Fesoterodine
August 29, 2011
- Switch OTC Versions of Pemirolast K Recommended for Approval
August 29, 2011
- BI Licenses ADCC Enhancing Technology from ProBioGen
August 29, 2011
- Caffeine Citrate Designated as an Orphan Drug
August 29, 2011
- JAMS Opposes Switch OTC Status for 3 Drugs Including Acarbose
August 29, 2011
- Eisai Establishes Marketing Subsidiary in Mexico
August 29, 2011
- JGA to Ask for Retention of “70% Rule”in Pricing of “First Generics”
August 29, 2011
- Mr Wolf of PhRMA Explains Advantages of VICP Introduced in US
August 29, 2011
- Shionogi Acquires 24.17% Stake in C&O of China
August 29, 2011
- Kyowa Pharm. Ind. Seeking M&A to Expand Product Line-up
August 29, 2011
- Saitama Police Send Case to Public Prosecutors Office against President of Saitama Pharm. Association
August 29, 2011
- US Court Orders Actelion to Pay Damages to Asahi Kasei Pharma for Stopping Fasudil's Development
August 29, 2011
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…